Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
LPCN

Lipocine (LPCN) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $1.72 -10.9% on the day -45.4% over 12 months 52-week range $1.72 – $11.26

Share price and insider trades

LPCN closeInsider buyInsider sale
051015NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $19,430 on 2026-09-29 · John W. HiguchiBought $27,132 on 2026-09-28 · John W. HiguchiBought $35,613 on 2026-09-30 · John W. HiguchiBought $50,500 on 2026-04-02 · Mahesh V. PatelBought $81,200 on 2026-04-07 · John W. HiguchiBought $302,900 on 2026-04-06 · John W. Higuchi, Mahesh V. Patel
Bought, 12 months$517K
Sold, 12 months$0
Insiders buying2
Insiders selling0

Lipocine insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $517K and 0 sold $0 of LPCN stock on the open market.

LPCN insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q2 2026: $435K bought (4 trades)$435KQ2 2026Q3 2026: $82K bought (3 trades)$82KQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$82K3—0
Q2 2026$435K4—0

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$14.2MBiotechnology
Profit margin0.0%Revenue growth -69.5%
Volume vs. 50-day570.8×Last 5 sessions
Insiders' paper profit−$86KOn all tracked purchases -16.6%

Summary

Over the past 12 months, 2 Lipocine Inc. insiders reported open-market purchases totaling $517K, while 0 insiders reported sales totaling $0. Among insiders with enough purchase history to measure, John W. Higuchi (Director) has the highest Insider Score at 68.

LPCN stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Oct 1SEC John W. HiguchiDirector Buy 15,970241,365 held (+7%) $2.23 $36K -22.9% 68
Oct 1SEC John W. HiguchiDirector Buy 9,037225,395 held (+4%) $2.15 $19K -20.0% 68
Sep 30SEC John W. HiguchiDirector Buy 12,561216,358 held (+6%) $2.16 $27K -20.4% 68
Apr 7SEC John W. HiguchiDirector Buy 40,000203,797 held (+24%) $2.03 $81K -15.3% 68
Apr 6SEC John W. HiguchiDirector Buy 123,000163,797 held (+301%) $2.05 $252K -16.1% 68
Apr 6SEC Mahesh V. PatelCEO Buy 25,000160,679 held (+18%) $2.03 $51K -15.3% 65
Apr 2SEC Mahesh V. PatelCEO Buy 25,000135,679 held (+23%) $2.02 $50K -14.9% 65

Insiders at Lipocine Inc.

InsiderBoughtSoldLast filingScore
John W. HiguchiDirector $416K — Oct 1, 2026 68
Mahesh V. PatelCEO $101K — Apr 6, 2026 65

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

LPCN stock: common questions

Are Lipocine Inc. insiders buying LPCN stock?

In the past 12 months, 2 insiders reported open-market purchases of LPCN worth $517K. The latest was Director John W. Higuchi bought $36K of LPCN at $2.23.

Are Lipocine Inc. insiders selling LPCN stock?

0 insiders reported sales worth $0 over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is LPCN's 52-week range?

Over the past year LPCN has traded between $1.72 and $11.26. It last closed at $1.72 on Oct 9, 2026.